AbbVie has multiple growth narratives to offset HUMIRA losses and clinical trial failures (e.g., venetoclax in MDS). In Q1, SKYRIZI generated a whopping $3.425 billion in net revenues ...

AbbVie is undervalued with strong EPS growth, rising immunology revenue, and a 3.43% yield. Check out ABBV's robust pipeline and long-term value.

AbbVie is facing a major challenge to its business in the coming years with the loss of patent protection for immunology behemoth Humira (adalimumab), which saw sales plunge by a third to $11.1 ...

AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece. The collaboration ...

The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

PORTLAND, OR, UNITED STATES, July 3, 2025 /EINPresswire / -- (Global value: USD 5.4 billion (2021) → USD 7.9 b ...

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.